← Back to Clinical Trials
Recruiting NCT05656586

Udall Project 2 Aim 2A&C

Trial Parameters

Condition Parkinson Disease
Sponsor University of Minnesota
Study Type OBSERVATIONAL
Phase N/A
Enrollment 36
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2023-01-01
Completion 2027-03-01
Interventions
observational-- no intervention

Brief Summary

This protocol will leverage the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC or RC DBS system to study the effects of globus pallidus internus, globus pallidus externus (GPi, GPe), and subthalamic nucleus (STN) DBS on: the wash-out and wash-in dynamics of motor behavior and local field potentials (LFPs) and correlations between fluctuations in gait and LFPs during activities of daily living (recorded over a minimum of 4 weeks). These experiments will elucidate the relationships between LFPs oscillations, lower limb function, postural control and gait performance.

Eligibility Criteria

Inclusion Criteria: * Receiving DBS therapy in GP for treatment of PD * Implanted with Medtronic Percept DBS system * At least 3 months since initial activation of the neurostimulator * For the "At Home" experiment only: participants with DBS settings that are sensing compatible. Exclusion Criteria: * history of musculoskeletal disorders that significantly affects the ability to perform the motor tasks in the specific experiment in question * history of dementia or cognitive impairment * other significant neurological disorder as determined by the PI * post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment * lack of capacity to consent (as identified by MaCAT-CR)

Related Trials